- For the vast majority of us, artificial intelligence (AI) is little more than a source of untrustworthy answers.
- The healthcare sector is putting the technology to more productive use by expediting diagnoses in conditions with high unmet needs.
- CeriBell (NASDAQ:CBLL) stands out in this regard thanks to a proprietary AI platform that identifies seizures and delirium meaningfully faster than legacy technology.
- Shares of CeriBell last traded at US$27.82, adding 131.26% year-over-year.
For the vast majority of us, AI and the large language models we access it through are little more than a source of untrustworthy answers, imprecise but usable images and soulless rendered voices untouched by the joys and sorrows of life. If we cast our gaze across the industrial spectrum, however, AI’s utility becomes readily apparent.
This article is a journalistic opinion piece written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
One sector where AI is making a tangible difference is healthcare and the reason why is easily recognizable. The technology is famously capable of scanning and analyzing truly massive quantities of data in seconds, well beyond what a human or traditional software could process in a reasonable amount of time. Poor health outcomes, for their part, represent very specific data points in a sea of otherwise healthy scans and tests. Theoretically, if an AI program is trained to identify an ailment with a high unmet need, the quality of care should improve.
A healthtech company putting this thesis in play is California-based CeriBell (NASDAQ:CBLL), market cap US$1.05 billion, whose FDA-approved CeriBell System, a point-of-care electroencephalography (EEG) platform, uses proprietary software and AI algorithms to rapidly diagnose neurological conditions in acute care settings, including delirium and non-convulsive seizures.
According to clinical data compiled by the company on its official website – scroll down for references and citations – up to one third of neurological critical care patients are at risk of seizures, up to 92% of which are non-convulsive, making them tricky to suss out.
CeriBell also found that at least 31% of ICU patients suffer from delirium, including up to 80% of mechanically ventilated patients, with standard of care assessments including the Confusion Assessment Method and the Intensive Care Delirium Screening Checklist falling short due to patient impairment and language barriers.
Traditional EEG technology’s approach to solving these problems is cumbersome at best, requiring an up to 30-minute setup, an up to 2-day results turnaround and the involvement of specially trained technicians and neurologists.
The CeriBell System, on the other hand, validated in 51 peer-reviewed publications, was found to yield EEG results in only 5 minutes, leveraging an easy-to-use headband or headcap, a portable recorder and a cloud-based portal requiring minimal training, radically reducing clinical assessment times and the potential for patient complications.
The system’s differentiated value-add has led to its adoption in more than 600 hospitals as of October 2025, a trajectory that has translated into 14 consecutive quarters of revenue growth – from US$9.5 million in Q1 2023 to US$28.1 million in Q2 2026 – including a hefty gross margin, most recently registering at 92%, which is allowing the healthtech company to pursue aggressive growth through innovation, sales and new hires.
Looking ahead, CeriBell is guiding for US$114-117 million in 2026 revenue, up by 28-31% year-over-year, with US$189.3 million in cash and credit available to continue building operational momentum.
Shares of CeriBell last traded at US$27.82, adding 131.26% year-over-year.
Join the discussion: Find out what investors are saying about this healthtech company on the CeriBell Inc. Bullboard and explore the rest of Stockhouse’s stock forums and message boards.